Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've noticed that too, I thought the ANDA approvals should have been received by now
whats goin on here?
shouldnt we have a timeline for ca 90 days for the merger with landapharma!?? 150 days now
Definitely a lot of potential here. It sounds like the company has a lot of know how. They just have to start making some product and this will get rolling.
abbreviated new drug application (ANDA)
maybe we'll get an update about the ANDA's 3 of them are pending
Over the last couple of days.
you got it yesterday?
I'm in for a few. When is business expected to start here? Looks like we have a long term winner.
The chart is looking very good here now. Does anyone think that this could be ten cents or more again in the near future?
Please request Stockcharts symbol-->
http://stockcharts.com/help/doku.php?id=support:feedback:symbol_request
bought more today
bought 2 pharmaceuticals now (ARGA & RXEI)
one of them can make a run like TTNP did! ;))
glad to have some company here lol
bought in today
based on shareholder-update we should hear any from the company soon
Looks like it. Hmmm, was that you on 1000 shares?
UP 60% .008, did ask just move to .01?
Thanx life keep me updated. On the back burner for now.
finally .005 is gone, we're on our way to higher levels imho
Yeah, near the bottom of all the ones I'm watching not to mention looking into. I need money yesterday-lol. Trading is a 24/7 job. You can get so lost in it before you know it the better part of a day has past.
it would be nice to see some volume back here again
Watching for now. Nice to know things are happening back stage.
yes I agree, we just need someone to slap that ask
Thanx TR, that sounds very encouraging. I will be watching closely for further developments.
No doubt the PPS doesn't reflect the potential of the company, but I think they need to get some financial issues in order first.
Honestly, I don't think so and I'm not sure the demand for ophthalmic products (pending ANDAs) will generate an abundance of revenue. But I can tell you the guys running the show there are a hell of a lot smarter than me, so who knows what they have up their sleeves.
I'm hoping a TTNP move would be possible here with the upcoming approvals
Yea, not sure what the hold up is. There in the process of moving some big-wigs around. I suspect this may have caused some delay with the appropriate SEC filings.
are they profitable?
LOL! Ohhhhhhhhhh...
I don't work for Landela directly, we prepare and submit thier applications for them. Didn't realize they had that info posted.
can't the company issue another PR soon?
90 days just to change the name? it's been 90 days
cool...it's on your website lol
Here's a summary based on an emial I received in February.
xxxxxxxxxxx,
We have had some recent changes at RxElite that I would like to inform you about. On January 27th RxElite sold its operating subsidiary RxElite Holdings and its associated anesthetic gas business to Piramal Healthcare Ltd.. Piramal Healthcare is a large India based pharmaceutical company, which you may know of, that is seeking to build a presence in the US. In a separate, but related, transaction Piramal has also made a tender offer to acquire MinRad Inc., the company that manufactured the anesthetic gas products for RxElite. As a result of this transaction Piramal will keep some of the RxElite staff, mainly sales, marketing and customer service personnel to support the ongoing anesthetic gas business. The employees staying with the business will move to a new office building in Eagle ID, probably in mid to late February, where we will focus on commercialization of our other products, development of new drug products and growing our Israel based API manufacturing site. Our new address will be 776 East Riverside Dr., Suite 150, Eagle ID, 83616. We have also changed the name of the company to Landela Pharmaceutical to avoid any confusion with the surviving RxElite Holdings anesthetic gas business. Please note that it will take us 90-120 days to change the name with the SEC so for contracts we should use RxElite, Inc. dba Landela Pharmaceutical for this interim period. There should be no impact to the strong relationship we have established with xxxxxx, we will continue to develop new products with the intent of selling them through the networks and systems created by RxElite. Please note the new phone numbers and addresses below. This transaction has been in the works for several months and we are pretty excited about these changes as they pave the way for future success of the company. Gene and I will work closely with xxxxx and xxxxx to update the pending and approved ANDAs with these changes and if either of you have any questions feel free to contact us.
Thanks and Best Regards,
Patrick Poisson
Vice President, Operations
How did you know this? I'm the one who filed them. We're currently sorting out some minor issues with the second application.
Thanx lifegear. Not bad @ all. Watching close here could be a mega hit for sure.
Share stats?--->
per knobias
Authorized Shares: 200,000,000
Source: 8-K ( 10/29/2007 )
Outstanding Shares: 119,705,157
Source: MGFS ( 11/11/2008 )
Would love to. On very close radar life. Do you know the SS?
8 boardmarks now, let's run this to dollars =)
Yes-I just saw that on...one of the 4 websites lol.
On February 2, 2009, RxElite, Inc. also commenced activities as “Landela Pharmaceutical.” The name change will allow the Company to distinguish itself from its former subsidiary, RxElite Holdings Inc. The Company fully intends to differentiate itself through products, marketing, and distribution channels to be solely known as Landela Pharmaceutical.
Finetech is a subsidiary of Landela
Trying to sort all this out between RXEI-Landela-Piramal-Finetech-API-Hard to follow without recent news connecting all the dots. So Pirmal owns all RXEI stock I guess. And that stock is still trading as RXEI? What is the O/S-A/S and float here? RXEI really needs to put out a PR that clears up the new structure of this whole thing and how everything ties together to get a clear picture.
they have 8 drugs....
Epoprostenol No
Huperzine A Regional R&D Work Completed
Iloprost No
Palonosetron No R&D Work Completed
Remifentanil No Paper Chemistry
Ropinirole No R&D Work Completed
Treprostinil No
Zafirlukast No R&D Work Completed
they've filed for two abbreviated new drug application (ANDA), maybe they're just waiting for approval before releasing news
another ANDA is still in process, filed before the other two
Watching. So now RXEI is now Landela Pharmaceutical? Still reading the new posts here and trying to understand what"s going on.Paramal Healthcare in India bought assets and RXEI has subsidiary/R#D-manufacturer in Isreal. Trying to put all this together with no recent PR"s.
UPDATED THE IBOX
Followers
|
10
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
220
|
Created
|
10/21/08
|
Type
|
Free
|
Moderators |
About RxElite, Inc. dba Landela Pharmaceutical
RxElite, Inc. dba Landela Pharmaceutical is a specialty pharmaceutical company that develops and markets generic prescription drug products in specialty generic markets. The Company also operates an Israeli subsidiary that manufactures and markets complex active pharmaceutical ingredients and provides research and development services to pharmaceutical companies throughout the world.
http://www.landelapharma.com/releases/57-rxelite-inc-shareholder-update
SUBSIDIARY: FINETECH PHARMACEUTICAL
http://www.finetechlabs.com/index.php?option=com_content&task=view&id=20&Itemid=29
RxElite, Inc. Shareholder Update |
Thursday, 12 February 2009 09:50 |
Meridian, Idaho, February 12, 2009: RxElite, Inc. [RXEI.PK] announced today that it has determined to suspend reporting currently with the SEC. On February 3, 2009, RxElite filed Form 15, Certificate and Notice of Termination of Registration under Section 12(g) of the Securities Exchange Act of 1934, and no longer will be required to file mandatory reports with the SEC. According to Earl Sullivan, Chairman and CEO, “We made this decision in consultation with our senior lenders after which our board authorized suspension of reporting as a measure designed to reduce overhead and compliance costs following our recent sale of RxElite Holdings Inc., our wholly owned U.S. subsidiary, to Piramal Healthcare Limited (India).”
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |